ctDNA Identifies Acquired Resistance Mechanisms to Savolitinib in MET+ Gastric Cancer
An early trial of AstraZeneca’s MET inhibitor savolitinib in gastric cancer revealed mutations that confer drug resistance.
PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2
Expression of the coding RNA PCAT-1 is associated with cisplatin resistance in gastric cancer, and suppressing PCAT-1 can re-sensitize cancer cells to... Read More
